Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

HLA Class I

  • Natalia Aptsiauri
  • Francisco Ruiz-Cabello Osuna
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_2766-7

Definition

The major histocompatibility complex (MHC) is a system of genes encoding molecules expressed on the cell surface that are required for antigen presentation to the immune system. In humans, this system is called human leukocyte antigen or HLA genes, since it was discovered through antigenic differences among white blood cells from different individuals in the search for polymorphic antigens to match for transplantation. HLA class I molecules are of key importance in the cell-mediated antitumor immune response against viral infections and transformed cells by presenting peptide antigens to cytotoxic T lymphocytes.

Characteristics

The classical HLA class I and class II molecules (HLA-ABC and HLA-DR, HLA-DP, HLA-DQ, respectively) are cell-surface glycoproteins closely related in structure and function. HLA class I molecules consist of two polypeptide chains, a heavy chain of 340 amino acids encoded in chromosome 6 and a light non-polymorphic chain, β2-microglobulin (β2-m),...

Keywords

Major Histocompatibility Complex Class Tumor Antigen Peptide High Major Histocompatibility Complex Spontaneous Metastasis Assay Bind Peptide Fragment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F (2007) MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 256:139–189.3CrossRefPubMedGoogle Scholar
  2. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet MA, Duggan-Keen M, Stern P (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 18:89–955CrossRefPubMedGoogle Scholar
  3. Garrido F, Cabrera T, Aptsiauri N (2010) “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127(2):249–256.4PubMedGoogle Scholar
  4. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3(11):999–1005.6CrossRefPubMedPubMedCentralGoogle Scholar
  5. Ruiz-Cabello F, Garrido F (1998) HLA and cancer: from research to clinical impact. Immunol Today 19:539–5427CrossRefPubMedGoogle Scholar
  6. Seliger B, Cabrera T, Garrido F, Ferrone F (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3–13CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Natalia Aptsiauri
    • 1
  • Francisco Ruiz-Cabello Osuna
    • 1
  1. 1.UGC Laboratorio Clínico Hospital Universitario Virgen de las Nieves Facultad de MedicinaUniversidad de GranadaGranadaSpain